Trial Profile
Study of Efficacy and Safety of Biologic Drugs in the Therapy of Rheumatoid Arthritis and Spondyloarthritis
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 01 Aug 2023
Price :
$35
*
At a glance
- Drugs Abatacept (Primary) ; Adalimumab (Primary) ; Baricitinib (Primary) ; Etanercept (Primary) ; Filgotinib (Primary) ; Infliximab (Primary) ; Methotrexate (Primary) ; Rituximab (Primary) ; Tocilizumab (Primary) ; Upadacitinib (Primary)
- Indications Ankylosing spondylitis; Psoriatic arthritis; Rheumatoid arthritis
- Focus Adverse reactions; Therapeutic Use
- Acronyms GISEA
- 03 Jun 2023 Results (n=1361) of a descriptive analysis assessing long-term retention rate of JAKis and influence of baseline population characteristics on treatment persistence presented at the 24th Annual Congress of the European League Against Rheumatism
- 01 Oct 2021 Results (n=278) assessing the effectiveness and drug retention rate of a second-line biologic therapy with TNFi or other MoA, after switching from a first-course treatment with either RTX, TCZ, or ABA in RA patients, published in the Clinical Rheumatology.
- 27 Sep 2020 Planned primary completion date changed from 1 May 2020 to 1 May 2022.